Company: Qiming Venture Partners
Description: Founded in 2006, Qiming Venture Partners has established itself as a prominent venture capital firm operating within the dynamic landscapes of both venture capital and private equity. With offices strategically situated in major cities such as Shanghai, Beijing, Suzhou, Hong Kong, and Singapore, Qiming Venture Partners is well-positioned to identify and support innovative companies across the Asia-Pacific region.
The firm currently manages a diverse portfolio comprising eleven U.S. Dollar funds and seven RMB funds, with a remarkable total of 95 billion in capital raised. Since its inception, Qiming Venture Partners has focused on investing in exceptional companies within the Technology and Consumer (TC) sectors, as well as the Healthcare industry, targeting businesses at both early and growth stages. Over the years, the firm has successfully backed more than 530 fast-growing and innovative enterprises, demonstrating a strong commitment to fostering entrepreneurial success.
A notable achievement for Qiming Venture Partners is that over 200 of its portfolio companies have accomplished successful exits through initial public offerings (IPOs) on prominent exchanges, including the New York Stock Exchange (NYSE), NASDAQ, Hong Kong Stock Exchange (HKEX), as well as the Shanghai and Shenzhen Stock Exchanges. Additionally, the firm has supported over 70 portfolio companies in reaching unicorn status, highlighting its ability to identify companies with significant growth potential.
Among its diverse portfolio, Qiming Venture Partners has backed some of the most influential firms in their respective sectors, including notable names such as Xiaomi (SEHK: 1810), Meituan (SEHK: 3690), Bilibili (NASDAQ: BILI), and Zhihu (NYSE: ZH), as well as Roborock (SHSE: 688169), Gan & Lee Pharmaceuticals (SHSE: 603087), and Tigermed (SZSE: 300347). The firm’s investments extend to other key players like Zai Lab (NASDAQ: ZLAB), CanSino Biologics (SEHK: 6185), Schrodinger (NASDAQ: SDGR), and New Horizon Health (SEHK: 6606), showcasing its far-reaching impact across various industries.
In addition to these well-known companies, Qiming Venture Partners has also supported emerging innovators such as Sanyou Medical (SHSE: 688085), AmoyDx (SZSE: 300685), Berry Genomics (SZSE: 000710), SinocellTech (SHSE: 688520), UBTech (SEHK: 9880), Yuanxin Technology, Caidya, Belief BioMed, WeRide, and Biren Technology, among many others. This extensive network of successful investments underscores Qiming Venture Partners' dedication to nurturing the next generation of trailblazing companies and their significant contributions to the economy and society at large.